Are Huntington’s and polyglutamine-based ataxias proteasome storage diseases?

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 5, 2003, Pages 562-571

  Goellner, Geoffrey M ^a   Rechsteiner, Martin ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamine; Q expansions; REG suppression

Indexed keywords

BRAIN PROTEIN; CHAPERONE; GLUTAMINE; MUTANT PROTEIN; PEPTIDE; POLYGLUTAMINE; PROTEASOME; PROTEIN; PROTEIN REG; UBIQUITIN; UNCLASSIFIED DRUG;

ATAXIA; CELL NUCLEUS INCLUSION BODY; CYTOPATHOLOGY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN ISOLATION; REVIEW; STORAGE DISEASE;

ANIMALS; ATAXIA; AUTOANTIGENS; CYSTEINE ENDOPEPTIDASES; GLUTAMINE; HUNTINGTON DISEASE; MICE; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; UBIQUITIN;

EID: 0037401277     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00388-6     Document Type: Review

References (108)

1. Abel A., Walcott J., Woods J., Duda J., Merry D.E. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Human Molecular Genetics. 10:2001;107-116.
2. Bailey C.K., Andriola I.F., Kampinga H.H., Merry D.E. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Human Molecular Genetics. 11:2002;515-523.
3. Bao Y.P., Cook L.J., O'Donovan D., Uyama E., Rubinsztein D.C. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. The Journal of Biological Chemistry. 277:2002;12263-12269.
4. Beal M.F., Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;3-4.
5. Bence N., Sampat R., Kopito R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
6. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;6809-6814.
7. Butler R., Leigh P.N., McPhaul M.J., Gallo J.-M. Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. Human Molecular Genetics. 7:1998;121-127.
8. Caplen N.J., Taylor J.P., Statham V.S., Tanaka F., Fire A., Morgan R.A. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Human Molecular Genetics. 11:2002;175-184.
9. Carmichael J., Chatellier J., Woolfson A., Milstein C., Fersht A.R., Rubinsztein D.C. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;9701-9705.
10. Cascio P., Call M., Petre B., Walz T., Goldberg A.L. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. The EMBO Journal. 21:2002;2636-2645.
11. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Human Molecular Genetics. 8:1999;673-682.
12. Chan H.Y.E., Warrick J.M., Gray-Board G.L., Paulson H.L., Bonini N.M. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Human Molecular Genetics. 9:2000;2811-2820.
13. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.-P., Cha J.-H.J., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in transgenic mouse model of Huntington disease. Nature Medicine. 6:2000;797-801.
14. Chun W., Lesort M., Tucholski J., Ross C.A., Johnson G.V. Tissue transglutaminase does not contribute to the formation of mutant Huntington aggregates. Journal of Cell Biology. 153:2001;25-34.
15. Chung K.K., Dawson V.L., Dawson T.M. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. TINS. 24:2001;S7-S14.
16. Cooper J.K., Schilling G., Peters M.F., Herring W.J., Sharp A.H., Kaminsky Z., Masone J., Khan F.A., Delanoy M., Borchelt D.R., Dawson V.L., Dawson T.M., Ross C.A. Truncated N-terminal fragments of Huntington with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Human Molecular Genetics. 7:1998;783-790.
17. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genetics. 19:1998;148-154.
18. Davidson J.D., Riley B., Burright E.N., Duvick L.A., Zoghbi H.Y., Orr H.T. Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein. Human Molecular Genetics. 9:2000;2305-2312.
19. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Nangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
20. de Cristofaro T., Affaitati A., Feliciello A., Avvedimento E.V., Varrone S. Polyglutamine-mediated aggregation and cell death. Biochemical and Biophysical Research Communications. 272:2000;816-821.
21. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of Huntington in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
22. Ding Q., Lewis J.J., Strum K.M., Dimayuga E., Bruce-Keller A.J., Dunn J.C., Keller J.N. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. The Journal of Biological Chemistry. 277:2002;13935-13942.
23. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296:2002;2238-2243.
24. Ellerby L.M., Hackam A.S., Propp S.S., Ellerby H.M., Rabizadeh S., Cashman N.R., Trifiro M.A., Pinsky L., Wellington C.L., Salvesen G.S., Hayden M.R., Bredesen D.E. Kenedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. Journal of Neurochemistry. 72:1999;185-195.
25. Emmerich N.P.N., Nussbaum A.K., Stevanovic S., Priemer M., Toes R.E.M., Rammensee H.-G., Schild H. The human 26S and 20S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. The Journal of Biological Chemistry. 275:2000;21140-21148.
26. Freeman T.B., Cicchetti F., Hauser R.A., Deacon T.W., Li X.-J., Hersch S.M., Nauert G.M., Sanberg P.R., Kordower J.H., Saporta S., Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;13877-13882.
27. Gerber H.-P., Seipel K., Georgiev O., Höfferer M., Hug M., Rusconi S., Schaffner W. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science. 263:1994;808-811.
28. Goldberg Y.P., Nicholson D.W., Rasper D.M., Kalchman M.A., Koide H.B., Graham R.K., Bromm M., Kazemi-Esfarjani P., Thornberry N.A., Vaillancourt J.P., Hayden M.R. Cleavage of Huntington by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics. 13:1996;442-449.
29. Green H. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell. 74:1993;955-956.
30. Gregori L., Fuchs C., Figueiredo-Pereira M.E., Van Nostrand W.E., Goldgaber D. Amyloid b-protein inhibits ubiquitin-dependent protein degradation in Vitro. The Journal of Biological Chemistry. 270:1995;19702-19708.
31. Gregori L., Hainfeld J.F., Simon M.N., Goldgaber D. Binding of amyloid b protein to the 20S proteasome. The Journal of Biological Chemistry. 272:1997;58-62.
32. Hackam A.S., Singaraja R., Wellington C.L., Metzler M., McCutcheon K., Zhang T., Kalchman M., Hayden M.R. The influence of Huntington protein size on nuclear localization and cellular toxicity. Journal of Cell Biology. 141:1998;1097-1105.
33. Hayashi M., Suzuki H., Kawashima S., Saido T.C., Inomata M. The behavior of calpain-generated N- and C-terminal fragments of talin in integrin-mediated signaling pathways. Archives of Biochemistry and Biophysics. 371:1999;133-141.
34. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.E. Inhibition of Huntington fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;6739-6744.
35. Hendil K.B., Khan S., Tanaka K. Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. The Biochemical Journal. 332:1998;749-754.
36. Holbert S., Denghien I., Kiechle T., Rosenblatt A., Wellington C., Hayden M.R., Margolis R.L., Ross C.A., Dausset J., Ferrante R.J., Neri C. The Gln-Ala repeat transcriptional activator CA150 interacts with Huntington: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;1811-1816.
37. Hughes R.E., Olson J.M. Therapeutic opportunities in polyglutamine disease. Nature Medicine. 7:2001;419-423.
38. Jana N.R., Tanaka M., Wang G.-H., Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal Huntington: their role in suppression of aggregation and cellular toxicity. Human Molecular Genetics. 9:2000;2009-2018.
39. Jana N.R., Zemskov E.A., Wang G., Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal Huntington induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human Molecular Genetics. 10:2001;1049-1059.
40. Kalchman M.A., Graham R.K., Xia G., Koide H.B., Hodgson J.G., Graham K.C., Goldberg Y.P., Gietz R.D., Pickart C.M., Hayden M.R. Huntington is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. The Journal of Biological Chemistry. 271:1996;19385-19394.
41. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nature Medicine. 8:2002;143-149.
42. Kaytor M.D., Warren S.T. Aberrant protein deposition and neurological disease. The Journal of Biological Chemistry. 274:1999;37507-37510.
43. Kazantsev A., Walker H.A., Slepko N., Bear J.E., Preisinger E., Steffan J.S., Zhu Y.Z., Gertler F.B., Housman D.E., Marsh J.L., Thompson L.M. A bivalent Huntington binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nature Genetics. 30:2002;367-376.
44. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 287:2000;1837-1840.
45. Khoshnan A., Ko J., Patterson P.H. Effects of intracellular expression of anti-Huntington antibodies of various specificities on mutant Huntington aggregation and toxicity. Proceedings of the National Academy of Sciences of the United States of America. 99:2002;1002-1007.
46. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 95:1998;41-53.
47. Kopp F., Dahlmann B., Kuehn L. Reconstitution of hybrid proteasomes from purified PA700-20 S complexes and PA28alphabeta activator: ultrastructure and peptidase activities. Journal of Molecular Biology. 313:2001;465-471.
48. Krobitsch S., Lindquist S. Aggregation of Huntington in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;1589-1594.
49. Kruger R., Eberhardt O., Riess O., Schultz L.B. Parkinson's disease: one biochemical pathway to fit all genes? Trends in Molecular Medicine. 8:2002;236-240.
50. La Spada A.R., Fu Y.H., Sopher B.L., Libby R.T., Wang X., Li L.Y., Einum D.D., Huang J., Possin D.E., Smith A.C., Martinez R.A., Koszdin K.L., Treuting P.M., Ware C.B., Hurley J.B., Ptacek L.J., Chen S. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7b. Neuron. 31:2001;913-927.
51. Lecerf J.M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., Huston J.S. Human single-chain Fv intrabodies counteract in situ Huntington aggregation in cellular models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;4764-4769.
52. Li J., Rechsteiner M. Molecular dissection of the 11 S REG (PA28) proteasome activators. Biochimie. 83:2001;373-383.
53. Li H., Li S.-H., Johnston H., Shelbourne P.F., Li X.-J. Amino-terminal fragments of mutant Huntington show selective accumulation in striatal neurons and synaptic toxicity. Nature Genetics. 25:2000;385-389.
54. Li S.-H., Lam S., Cheng A.L., Li X.-J. Intranuclear Huntington increases the expression of caspase-1 and induces apoptosis. Human Molecular Genetics. 9:2000;2859-2867.
55. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.-H.J., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human Molecular Genetics. 9:2000;1259-1271.
56. Margolis R.L., Ross C.A. Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends in Molecular Medicine. 7:2001;479-482.
57. Marsh J.L., Walker H., Theisen H., Zhu Y.-Z., Fielder T., Purcell J., Thompson L.M. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Human Molecular Genetics. 9:2000;13025.
58. Martin-Aparicio E., Yamamoto A., Hernandez F., Hen R., Avila J., Lucas J.J. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. Journal of Neuroscience. 21:2001;8772-8781.
59. Martindale D., Hackam A., Wieczorek A., Ellerlby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S.U., Bredesen D.E., Tufaro F., Hayden M.R. Length of Huntington and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nature Genetics. 18:1998;150-154.
60. Meriin A.B., Zhang X., He X., Newnam G.P., Chernoff Y.O., Sherman M.Y. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1b. Journal of Cell Biology. 157:2002;997-1004.
61. Merry E.E., Kobayashi Y., Bailey C.K., Taye A.A., Fischbeck K.H. Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Human Molecular Genetics. 7:1998;693-701.
62. Murata S., Kawahara H., Tohma S., Yamamoto K., Kasahara M., Nabeshima Y., Tanaka K., Chiba T. Growth retardation in mice lacking the proteasome activator PA28gamma. The Journal of Biological Chemistry. 274:1999;38211-38215.
63. Nagai Y., Tucker T., Ren H., Kenan D.J., Henderson B.S., Keene J.D., Strittmatter W.J., Burke J.R. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. The Journal of Biological Chemistry. 275:2000;10437-10442.
64. Nucifora F.C. Jr., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by Huntington and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
65. Nussbaum A.K., Dick T.P., Keilholz W., Schirle M., Stevanovic S., Dietz K., Heinemeyer W., Groll M., Wolf D.H., Huber R., Rammensee H.-G., Schild H. Cleavage motifs of the yeast 20S proteasome b subunits deduced from digests of enolase 1. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;12504-12509.
66. Okazawa H., Rich T., Chang A., Lin X., Waragai M., Kajikawa M., Enokido Y., Komuro A., Kato S., Shibata M., Hatanaka H., Mouradian M.M., Sudol M., Kanazawa I. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron. 34:2002;701-713.
67. Ona V.O., Li M., Vonsattel J.P.G., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.-J., Steig P.E., Yuan J., Penney J.B., Young A.B., Cha J.-H.J., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:1999;263-267.
68. Opal P., Zoghbi H.Y. The role of chaperones in polyglutamine disease. Trends in Molecular Medicine. 8:2002;232-236.
69. Ordway J.M., Tallaksen-Greene S., Gutekunst C.-A., Bernstein E.M., Dure L.S. IV, Lindsey R., Hersch S.M., Jope R.S., Albin R.L., Detloff P.J. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 91:1997;753-763.
70. Paulson H.L. Human Genetics'99: trinucleotide repeats. Protein fate in neurodegenerative proteinopathies: polyglutamine disease join the (mis)fold. American Journal of Human Genetics. 64:1999;339-345.
71. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.-L., Fischbeck K.H., Pittman R.N. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 19:1997;333-344.
72. Perez M.K., Paulson H.L., Pendse S.J., Saionz S.J., Bonini N.M., Pittman R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. Journal of Cell Biology. 143:1998;1457-1470.
73. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends in Biochemical Science. 24:1999;58-63.
74. Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;5355-5458.
75. Peters P.J., Ning K., Palacios F., Boshans R.L., Kazantsev A., Thompson L.M., Woodman B., Bates G.P., D'Souza-Schorey C. Arfaptin 2 regulates the aggregation of mutant Huntington protein. Nature Cell Biology. 4:2002;240-245.
76. Pfaff M., Du X., Ginsberg M.H. Calpain cleavage of integrin b cytoplasmic domains. FEBS Letters. 460:1999;17-22.
77. Rechsteiner M., Realini C., Ustrell V. The proteasome activator 11S REG (PA28) and class I antigen presentation. Biochemical Journal. 345:2000;1-15.
78. Saito K., Elce J.S., Hamos J.E., Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America. 90:1993;2628-2632.
79. Sanchez I., Xu C.-J., Juo P., Kakizaka A., Blenis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron. 22:1999;623-633.
80. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntington acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66.
81. Schilling G., Wood J.D., Duan K., Slunt H.H., Gonzales V., Yamada M., Cooper J.K., Margolis R.L., Jenkins N.A., Copeland N.G., Takahashi H., Tsuji S., Price D.L., Borchelt D.R., Ross C.A. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron. 24:1999;275-286.
82. Schmidt T., Lindenberg K.S., Krebs A., Schols L., Laccone F., Herms J., Rechsteiner M., Riess O., Landwehrmeyer G.B. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Annals of Neurology. 51:2002;302-310.
83. Senut M.-C., Suhr S.T., Kaspar B., Gage F.H. Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. Journal of Neuroscience. 20:2000;219-229.
84. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., Kimura T., Koide R., Nozaki K., Sano Y., Ishiguro H., Sakoe K., Ooshiima T., Sato A., Ikeuchi T., Oyake M., Sato T., Aoyagi Y., Hozumi I., Nagatsu T., Takiyama Y., Nishizawa M., Goto J., Kanazawa I., Davidson I., Tanese N., Takahashi H., Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nature Genetics. 26:2000;29-36.
85. Skinner P.J., Koshy B.T., Cummings C.J., Klement I.A., Helin K., Servadio A., Zoghbi H.Y., Orr H.T. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature. 389:1997;971-978.
86. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.-Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;6763-6768.
87. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Paptel K., DeMartino G.N., Marcelli M., Weigel N.L., Mancini M.A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Human Molecular Genetics. 8:1999;731-741.
88. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics. 10:2001;919-926.
89. Taylor J.P., Fischbeck K.H. Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention? Trends in Molecular Medicine. 8:2002;195-197.
90. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science. 296:2002;1991-1995.
91. Toes R.E.M., Nussbaum A.K., Degermann S., Schirle M., Emmerich N.P.N., Kraft M., Laplace C., Zwinderman A., Dick T.P., Muller J., Schonfisch B., Schmid C., Fehling H.-J., Stevanovic S., Rammensee H.G., Schild H. Discrete cleavage motif of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. The Journal of Experimental Medicine. 194:2001;1-12.
92. Verhoef L.G.G.C., Lindsten K., Masucci M.G., Dantuma N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Human Molecular Genetics. 11:2002;2689-2700.
93. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H., Wanker E.E. Accumulation of mutant Huntington fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Molecular Biology of the Cell. 12:2001;1393-1407.
94. Wang G.-H., Sawai N., Kotliarova S., Kanazawa I., Nukina N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Human Molecular Genetics. 9:2000;1795-1803.
95. Waragai M., Lammers C.-H., Takeuchi S., Imafuku I., Udagawa Y., Kanazawa I., Kawabata M., Mouradian M.M., Okazawa H. PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Human Molecular Genetics. 8:1999;977-987.
96. Waragai M., Junn E., Kajikawa M., Takeuchi S., Kanazawa I., Shibata M., Mouradian M.M., Okazawa H. PQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domain. Biochemical and Biophysical Research Communications. 273:2000;592-595.
97. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70b. Nature Genetics. 23:1999;425-428.
98. Watase K., Weeber E.J., Xu B., Antalffy B., Yuva-Paylor L., Hashimoto K., Kano M., Atkinson R., Sun Y., Armstrong D.L., Sweatt J.D., Orr H.T., Paylor R., Zoghbi H.Y. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 34:2002;905-919.
99. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273:1998;9158-9167.
100. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A.S., Thornberry N., Nicholson D.W., Bredesen D.E., Hayden M.R. Inhibiting caspase cleavage of Huntington reduces toxicity and aggregate formation in neuronal and nonneuronal cells. The Journal of Biological Chemistry. 275:2000;19831-19838.
101. Wheeler V.C., White J.K., Gutekunst C.-A., Vrbanac V., Weaver M., Li X.-J., Li S.-H., Yi H., Vonsattel J.-P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of Huntington in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Human Molecular Genetics. 9:2000;503-513.
102. Wyttenbach A., Carmichael J., Swartz J., Furlong R.A., Narain Y., Rankin J., Rubinsztein D.C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;2898-2903.
103. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell M., Schapira A., Orntoft T.F., Kato K., Rubinsztein D.C. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Human Molecular Genetics. 10:2001;1829-1845.
104. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A.P., Rubinsztein D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by Huntington. Human Molecular Genetics. 11:2002;1137-1151.
105. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:2000;57-66.
106. Yvert G., Lindenberg K.S., Picaud S., Landwehrmeyer G.B., Sahel J.-A., Mandel J.-L. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Human Molecular Genetics. 9:2000;2491-2506.
107. Zatloukal K., Stumptner C., Fuchsbichler A., Heid H., Schnoelzer M., Kenner L., Kleinert R., Prinz M., Aguzzi A., Denk H. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. American Journal of Pathology. 160:2002;255-263.
108. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annual Review of Neuroscience. 23:2000;217-247.